Cipla to launch Cinacalcet Hydrochloride tablets, a generic version of Sensipar

Cipla said, its cinacalcet hydrochloride tablets in the strengths of 30mg, 60mg and 90mg) is generic therapeutic equivalent version of Sensipar, a branded drug marketed by Amgen Inc.

New Delhi: Drug major Cipla and it's subsidiary Cipla USA Wednesday announced a phased launch of generic cinacalcet hydrochloride tablets, used in the treatment of secondary hyperparathyroidism(HPT) in adult patients with chronic kidney disease on dialysis, in the US market. The launch, however, is a subject of ongoing litigation, Cipla said in a regulatory filing.

Cipla said, its cinacalcet hydrochloride tablets in the strengths of 30mg, 60mg and 90mg) is generic therapeutic equivalent version of Sensipar, a branded drug marketed by Amgen Inc.

Cinacalcet is a drug that acts as a calcimimetic by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe.

Also Read: Cipla to acquire 11.71 per cent stake in Wellthy Therapeutics

Cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis, for the treatment of hypercalcemia in adult patients with Parathyroid Carcinoma, and for treatment of severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.

Headquartered in Mumbai, Cipla multinational pharmaceutical and biotechnology company. The company primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.

Also Read: Cipla gets USFDA nod for Medroxyprogesterone injectable